TW202328191A - 使用her3抗原結合分子的癌症之治療及預防 - Google Patents

使用her3抗原結合分子的癌症之治療及預防 Download PDF

Info

Publication number
TW202328191A
TW202328191A TW111133471A TW111133471A TW202328191A TW 202328191 A TW202328191 A TW 202328191A TW 111133471 A TW111133471 A TW 111133471A TW 111133471 A TW111133471 A TW 111133471A TW 202328191 A TW202328191 A TW 202328191A
Authority
TW
Taiwan
Prior art keywords
amino acid
acid sequence
antigen
seq
binding molecule
Prior art date
Application number
TW111133471A
Other languages
English (en)
Chinese (zh)
Inventor
奈傑爾 衛斯伍德
哈利特 渥特斯
蓋文 哈爾伯特
珍妮佛 Ｌ 克雷根
思宇 關
科庫普 傑洛米 波尹德
皮爾斯 英葛蘭
迪普蒂 薩卡
Original Assignee
英商癌症研究科技有限公司
新加坡商蜂鳥生物科技私人有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 英商癌症研究科技有限公司, 新加坡商蜂鳥生物科技私人有限公司 filed Critical 英商癌症研究科技有限公司
Publication of TW202328191A publication Critical patent/TW202328191A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW111133471A 2021-09-03 2022-09-02 使用her3抗原結合分子的癌症之治療及預防 TW202328191A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG10202109667X 2021-09-03
SG10202109667X 2021-09-03

Publications (1)

Publication Number Publication Date
TW202328191A true TW202328191A (zh) 2023-07-16

Family

ID=83438993

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111133471A TW202328191A (zh) 2021-09-03 2022-09-02 使用her3抗原結合分子的癌症之治療及預防

Country Status (7)

Country Link
US (1) US20250122303A1 (cg-RX-API-DMAC10.html)
EP (1) EP4396238A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024536719A (cg-RX-API-DMAC10.html)
KR (1) KR20240110556A (cg-RX-API-DMAC10.html)
CN (1) CN118541395A (cg-RX-API-DMAC10.html)
TW (1) TW202328191A (cg-RX-API-DMAC10.html)
WO (1) WO2023031435A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260026009A (ko) 2023-04-06 2026-02-25 허밍버드 바이오사이언스 피티이. 엘티디. Her3 항원 결합 분자를 이용한 암의 치료 및 예방
CN120446468B (zh) * 2025-07-07 2025-09-26 美康生物科技股份有限公司 一种血清游离轻链检测试剂及检测方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AR094403A1 (es) * 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
WO2014131694A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
US20160319253A1 (en) 2013-12-19 2016-11-03 National Cancer Center Novel fusion genes as factors responsible for gastric cancer
JP7737220B2 (ja) 2017-03-31 2025-09-10 メルス ナムローゼ フェンノートシャップ ＮＲＧ１融合遺伝子を有する細胞の処置における使用のためのＥｒｂＢ－２及びＥｒｂＢ３結合二重特異性抗体
CN111527103A (zh) 2017-09-08 2020-08-11 科罗拉多大学董事会,法人团体 用于治疗或预防her驱动的抗药性癌症的化合物、组合物和方法
WO2019241893A2 (en) * 2018-06-22 2019-12-26 Crd Pharmaceuticals Inc Anti-her3 antibody and uses thereof
GB201913079D0 (en) * 2019-09-11 2019-10-23 Hummingbird Bioscience Holdings Pte Ltd Treatment and prevention of cancer using her3 antigen-binding molecules

Also Published As

Publication number Publication date
JP2024536719A (ja) 2024-10-08
EP4396238A1 (en) 2024-07-10
US20250122303A1 (en) 2025-04-17
WO2023031435A9 (en) 2024-05-02
CN118541395A (zh) 2024-08-23
WO2023031435A1 (en) 2023-03-09
KR20240110556A (ko) 2024-07-15

Similar Documents

Publication Publication Date Title
JP7825000B2 (ja) Ｈｅｒ３抗原結合性分子
EP3818086B1 (en) Treatment and prevention of cancer using her3 antigen-binding molecules
US20250122303A1 (en) Treatment and prevention of cancer using her3 antigen-binding molecules
HK40026637B (en) Her3 antigen-binding molecules
HK40026637A (en) Her3 antigen-binding molecules